updated 10/21/2010 7:19:04 AM ET 2010-10-21T11:19:04

DALLAS, Oct. 21, 2010 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring VIVUS Inc. (Nasdaq:VVUS). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: www.microstockprofit.com/lp/VVUS

VIVUS Inc. (VVUS) is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes, obstructive sleep apnea and sexual health. The Company's lead product in clinical development, Qnexa, has completed phase III clinical trials for the treatment of obesity and a new drug agreement (NDA) has been filed and accepted by the U.S. Food and Drug Administration (FDA), with an action date of October 28, 2010. Qnexa is also in phase II clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VVUS is in phase III development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction.

Message Board Search for VVUS: http://www.boardcentral.com/boards/VVUS

In the report, the analyst notes:

"VVUS's Qnexa is currently under U.S. Food and Drug Administration (FDA) review for the treatment of obesity. Qnexa is a once-a-day, proprietary, oral, controlled-release formulation of low dose phentermine and topiramate, which is believed to address both appetite and satiety - the two main mechanisms that impact eating behavior - in one capsule ...

"The Company in September said patients taking the highest dose of Qnexa lost an average of 26 pounds, or 11.4% of their body weight, while those taking a placebo had weight loss of 2.5%. The results came in better than the previously reported one-year weight loss of 10.4%."

To read the entire report visit: www.microstockprofit.com/lp/VVUS

See what investors are saying about VVUS at http://www.stockhideout.com

Get breaking news on VVUS at http://thestockmarketwatch.com/

MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: http://www.microstockprofit.com

MicroStockProfit.com Disclosure

MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 3.79%
$30K home equity loan FICO 4.99%
$75K home equity loan FICO 4.69%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.83%
Cash Back Cards 17.80%
Rewards Cards 17.18%
Source: Bankrate.com